Abeer Griggs
Internal Medicine · Neptune, NJNPI 1861669137
Payments from drug & device makers
Across 106 payments — averaging $13.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$221
- AstraZeneca$220
- AbbVie$216
- Zimmer Biomet$143
- Novo Nordisk$139
- Johnson & Johnson$135
- plus $319 from 14 others
What the payments were for
- Food & beverage$1,394100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 24 | $221 |
| AstraZeneca | 17 | $220 |
| AbbVie(2 entities) | 19 | $216 |
| Zimmer Biomet | 1 | $143 |
| Novo Nordisk | 10 | $139 |
| Johnson & Johnson | 11 | $135 |
| Amarin Pharma, Inc. | 4 | $52 |
| Bayer | 3 | $48 |
| Abbott | 2 | $29 |
| Biohaven Pharmaceuticals, Inc. | 2 | $25 |
| Lilly USA, LLC | 2 | $24 |
| Boehringer Ingelheim | 2 | $24 |
| Scilex Pharmaceuticals Inc. | 2 | $23 |
| Exact Sciences | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Novartis | 1 | $13 |
| Amgen | 1 | $13 |
| Astellas Pharma US Inc | 1 | $13 |
| Valeritas, Inc. | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ROSA-Knee$143
How this compares
$1,394 in reported general payments places this provider in the 70th percentile of 4,032 internal medicine providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 43 | $33,585 |
| XareltoRivaroxaban | 12 | $17,897 |
| OzempicSemaglutide | 14 | $14,086 |
| SynthroidLevothyroxine Sodium | 28 | $2,038 |
| Valsartan | 48 | $1,400 |
| Levothyroxine Sodium | 71 | $1,322 |
| Rosuvastatin Calcium | 65 | $1,017 |
| Atorvastatin Calcium | 110 | $887 |
| Pantoprazole Sodium | 31 | $707 |
| Metoprolol Succinate | 31 | $672 |
| Gabapentin | 25 | $448 |
| Lansoprazole | 13 | $445 |
| Nebivolol Hcl | 11 | $438 |
| Losartan Potassium | 40 | $436 |
| Amlodipine Besylate | 46 | $405 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $221 | $33,58543 claims |
| Johnson & JohnsonXarelto | $135 | $17,89712 claims |
| Novo NordiskOzempic | $139 | $14,08614 claims |
| AbbVieSynthroid | $216 | $2,03828 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Neptune
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.